In recent years, the ICB that targets PD-1/PD-L1 axis (e.g., perbrolizumab) has been approved as an ideal immunotherapy for breast cancer, while it is prone to benefit the patients marked by high TILs infiltration and immune checkpoint expression in tumor tissues [53]. This evidence concerns the gene CD274 and breast carcinoma.